Printer Friendly

Hydra Biosciences and Boehringer Ingelheim Collaboration Initiates Clinical Trial of TRPC4/5 Inhibitor for CNS Disorders.

M2 PHARMA-November 3, 2017-Hydra Biosciences and Boehringer Ingelheim Collaboration Initiates Clinical Trial of TRPC4/5 Inhibitor for CNS Disorders

(C)2017 M2 COMMUNICATIONS

- Cambridge, Massachusetts-based ion channels specialist Hydra Biosciences, Inc. partner Boehringer Ingelheim has initiated a Phase 1 clinical trial in healthy volunteers to evaluate a TRPC4/5 inhibitor compound for the treatment of central nervous system diseases (CNS) and disorders, including depression and anxiety, the company said.

The trial represents one of two ongoing collaborations between Hydra and Boehringer Ingelheim. The other is a worldwide research collaboration and license agreement to identify small-molecule TRP inhibitors with a primary focus on the treatment of renal diseases and disorders.

Under the terms of both collaboration agreements, the companies will work together to identify and advance candidate inhibitors.

Boehringer Ingelheim is responsible for the global development and commercialization of the inhibitors emerging from the collaborations.

Hydra received an upfront payment, additional research funding, and is eligible to receive milestone payments and tiered royalty payments on future product sales.

With its collaborative philosophy, Boehringer Ingelheim remains committed to R and D focused on understanding key symptoms present in different types of mental illness.

Privately held Hydra Biosciences develops drugs to treat pain, inflammation, renal disease, CNS, and pulmonary disease using its expertise in novel ion channels. The company's proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 3, 2017
Words:244
Previous Article:Seattle Genetics Files sBLA to FDA for Adcetris for Treatment of Hodgkin Lymphoma.
Next Article:ENDEAR Study Results of Spinraza for the Treatment of SMA Published in NEMJ.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters